美浮特®皮肤抗菌液联合菲嘉®皮肤抗菌液治疗甲真菌病的临床研究

中国真菌学杂志　 2023, Vol. 18 　Issue (1): 42-46.

美浮特^®皮肤抗菌液联合菲嘉^®皮肤抗菌液治疗甲真菌病的临床研究

徐晓光¹, 尹建凯², 刘竹¹, 郑锐¹, 刘维达³, 温海⁴

1. 上海浮美皮肤科门诊部, 上海 201107;
2. 江阴浮美皮肤病门诊部, 无锡 214433;
3. 中国医学科学院北京协和医学院皮肤病研究所, 南京 210042;
4. 上海长征医院, 上海 200003

收稿日期:2023-02-02 发布日期:2023-03-17
通讯作者: 刘维达,E-mail:liumyco@hotmail.com;温海,E-mail:wenhai98@sohu.com E-mail:liumyco@hotmail.com;wenhai98@sohu.com
作者简介:徐晓光,男(汉族),博士,博士后.E-mail:gardenspader@163.com

Efficacy and safety of Meifute^® antifungal solution combined with Feijia^® antifungal solution in the treatment of onychomycosis

XU Xiaoguang¹, YIN Jiankai², LIU Zhu¹, ZHENG Rui¹, LIU Weida³, WEN Hai⁴

1. Shanghai Fumei Dermatology Clinic, Shanghai 201107, China;
2. Jiangyin Fumei Dermatology Clinic, Wuxi 214433, China;
3. Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China;
4. Shanghai Changzheng Hospital, Shanghai 200003, China

Received:2023-02-02 Published:2023-03-17

摘要/Abstract

摘要： 目的观察美浮特^®皮肤抗菌液联合菲嘉^®皮肤抗菌液治疗甲真菌病的疗效及安全性。方法从2020年12月至2022年11月于浮美连锁门诊入组120例患者进行治疗。先以美浮特^®皮肤抗菌液泡足治疗,再以菲嘉^®皮肤抗菌液泡甲治疗每周1次,常规治疗28周,最后再给予1次美浮特^®皮肤抗菌液巩固治疗。以治疗前后病甲改变情况评估疗效,记录不良事件,并于疗程完成后进行治疗满意度问卷调查。结果 112例患者完成研究,共纳入病甲588个。疗效及满意度:总有效率58.0%(341/588),痊愈率20.6%(121/588),患者总体满意度为93.8%(105/112)。安全性:不良反应均为局部症状,如甲下出血(2例)、甲周脱皮(4例)、皮肤轻度红肿(6例)、轻到中度的烧灼感或刺痛感(16例),所有患者均可耐受治疗过程,未发生严重不良反应。结论美浮特^®皮肤抗菌液联合菲嘉^®皮肤抗菌液治疗甲真菌病操作简便、疗效显著、安全性好、依从性高,不失为一种临床可选择的甲真菌病治疗方法。

关键词: 抗真菌, 甲真菌病, 治疗

Abstract: Objective To evaluate the efficacy and safety of Meifute^® antifungal solution combined with Feijia^® antifungal solution in the treatment of onychomycosis. Methods From December 2020 to November 2022, 120 patients were enrolled in Fumei Outpatient Departments for this study. First of all, a single-session soak in Meifute^® antifungal solution was used to treat tinea pedis; and then, diseased nails were treated with Feijia^® antifungal solution once a week for 28 weeks routinely; finally, another time of Meifute^® antifungal solution treatment was given to consolidate the effect. Efficacy and safety evaluation was performed after treatment, and a questionnaire survey of treatment satisfaction was carried out after the completion of the treatment course. Results Finally 112 patients completed the study and 588 nails were included. Efficacy and satisfaction:overall effective rate was 58.0% (341/588), the cure rate was 20.6% (121/588), and the comprehensive satisfactory rate was 93.8% (105/112). The efficacy of the first toenail (52.9%) was lower than that of other toenails (60.7%). And there was no significant difference in the clinical response rate between DLSO (56.6%) and TDO (61.4%). Safety:The adverse reactions were all local symptoms, such as subungual hemorrhage (2 cases), exfoliation of epidermis around nails (4 cases), mild redness and swelling of skin (6 cases), mild to moderate burning or tingling (16 cases) after soak. All patients could tolerate the process without serious adverse reactions. Conclusion The use of Meifute^® antifungal solution combined with Feijia^® antifungal solution is simple, effective, safe, and highly compliant in the treatment of onychomycosis, so it can be regarded as a clinical alternative treatment for onychomycosis.

Key words: antifungal, onychomycosis, treatment

中图分类号:

R756.4

徐晓光, 尹建凯, 刘竹, 郑锐, 刘维达, 温海. 美浮特^®皮肤抗菌液联合菲嘉^®皮肤抗菌液治疗甲真菌病的临床研究[J]. 中国真菌学杂志, 2023, 18(1): 42-46.

XU Xiaoguang, YIN Jiankai, LIU Zhu, ZHENG Rui, LIU Weida, WEN Hai. Efficacy and safety of Meifute^® antifungal solution combined with Feijia^® antifungal solution in the treatment of onychomycosis[J]. Chinese Journal of Mycology, 2023, 18(1): 42-46.

参考文献

[1] 甲真菌病指南专家工作组. 中国甲真菌病诊疗指南(2021年版)[J]. 中国真菌学杂志,2022,17(1):1-7.
[2] SONG G, ZHANG M J, LIU W D, et al. Epidemiology of onychomycosis in Chinese mainland:a 30-year retrospective study[J]. Mycopathologia, 2022,187(4):323-331.
[3] BODMAN M A, KRISHNAMURTHY K. Onychomycosis. StatPearls Publishing,2022.https://www.ncbi.nlm.nih.gov/books/NBK441853/.
[4] LIPNER S R, SCHER R K. Onychomycosis:Clinical overview and diagnosis[J]. J Am Acad Dermatol, 2019, 80(4):835-851.
[5] GUPTA A K, STEC N, SUMMERBELL R C, et al. Onychomycosis:a review[J]. J Eur Acad Dermatol Venereol, 2020, 34(9):1972-1990.
[6] STEWART C R, ALGU L, KAMRAN R, et al. Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes:a systematic review[J]. J Am Acad Dermatol, 2021, 85(5):1227-1239.
[7] FALOTICO J M, LIPNER S R. Updated perspectives on the diagnosis and management of onychomycosis[J]. Clin Cosmet Investig Dermatol, 2022, 15:1933-1957.DOI:10.2147/CCID.S362635.
[8] GUPTA A K, VENKATARAMAN M, RENAUD H J, et al. A paradigm shift in the treatment and management of onychomycosis[J]. Skin Appendage Disord, 2021, 7(5):351-358.
[9] 王冲,李明,王秀丽,等. 美浮特皮肤抗菌液治疗足癣多中心临床研究[J]. 中国真菌学杂志,2013,8(4):220-227.
[10] JEFFCOATE W J, MUSGROVE A J, LINCOLN N B. Using image J to document healing in ulcers of the foot in diabetes[J]. Int Wound J, 2017, 14(6):1137-1139.
[11] 潘炜华. 2015年版中国甲真菌病诊疗指南解读[J].世界临床药物,2016,37(2):73-76.
[12] VLAHOVIC T C, GUPTA A K. Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients[J]. Expert Rev Anti Infect Ther, 2022, 20(1):3-15.
[13] FOLEY K, GUPTA A K, VERSTEEG S, et al. Topical and device-based treatments for fungal infections of the toenails[J]. Cochrane Database Syst Rev, 2020, 1(1):CD012093.
[14] GUPTA A K, VENKATARAMAN M, TALUKDER M. Onychomycosis in older adults:prevalence, diagnosis, and management[J]. Drugs Aging, 2022, 39(3):191-198.
[15] SALAKSHNA N, BUNYARATAVE S, MATTHAPAN L, et al. A cohort study of risk factors, clinical presentations, and outcomes for dermatophyte, nondermatophyte, and mixed toenail infections[J]. J Am Acad Dermatol, 2018, 79(6):1145-1146.
[16] 朱红梅,温海,许景峰,等. 美浮特皮肤抗菌液治疗部队足癣患者的疗效研究[J]. 中国真菌学杂志,2015,10(3):158-162.
[17] 史冬梅,顾克斌,沈永年,等. 美浮特皮肤抗菌液对致足癣真菌抗真菌后效应的体外研究[J]. 中国真菌学杂志,2014,9(2):88-92.
[18] 钟瑜,林少婷,覃芳敏,等. 苯扎氯铵消毒剂的抗菌性能研究[J]. 广东化工,2019,46(15):36-38.
[19] CHOI H, KIM K J, LEE D G. Antifungal activity of the cationic antimicrobial polymer-polyhexamethylene guanidine hydrochloride and its mode of action[J]. Fungal Biol, 2017, 121(1):53-60.
[20] GUPTA A K, WANG T, COOPER E A. Dermatophytomas:clinical overview and treatment[J]. J Fungi (Basel), 2022, 8(7):742.
[21] CHETANA K, MENON R, DAVID B G. Onychoscopic evaluation of onychomycosis in a tertiary care teaching hospital:a cross-sectional study from South India[J]. Int J Dermatol, 2018, 57(7):837-842.
[22] GUPTA A K, VERSTEEG S G, SHEAR N H, et al. A practical guide to curing onychomycosis:how to maximize cure at the patient, organism, treatment, and environmental level[J]. Am J Clin Dermatol, 2019, 20(1):123-133.
[23] 中国中西医结合学会皮肤性病专业委员会真菌学组,中国医师协会皮肤科医师分会真菌亚专业委员会,中华医学会皮肤病学分会真菌学组. 手癣和足癣诊疗指南(2017修订版)[J]. 中国真菌学杂志,2017,12(6):321-324.